Boryung Pharma posts upbeat Q1 earnings, but outlook cloudy
IndustryApr 24, 2020
Boryung Pharmaceutical on Friday announced over 40 percent on-year increase in its operating profit in the first quarter, but also expressed concerns for the next quarter. The company’s consolidated revenue for the first quarter rose 13 percent to 134.2 billion won ($109 million), while operating profit rose 42 percent to 13.3 billion won and net profit slid 6 percent to 8.3 billion won. It said its anti-hypertension drug Kanarb’s domestic performance led to good business last year